세계의 인유두종 바이러스(HPV) 백신 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 질환별, 유통 채널별, 지역별, 부문 예측(2025-2030년)

Human Papillomavirus Vaccines Market Growth & Trends:

The global Human Papillomavirus vaccines market size is expected to reach USD 14.03 billion by 2030, registering a CAGR of 8.82% from 2025 to 2030, according to a new report by Grand View Research, Inc., driven by several key factors. The increasing involvement of governments and international health organizations in promoting HPV vaccination is significantly propelling market growth. For instance, in November 2024, the Ministry of Health of the Lao People's Democratic Republic (Lao PDR), in collaboration with UNICEF, the World Health Organization (WHO), and Gavi, the Vaccine Alliance-with support from the Government of Australia-officially launched the 2024 Human Papillomavirus (HPV) immunization campaign. Many countries have introduced HPV vaccines into their national immunization schedules, often with funding support from global organizations such as GAVI, WHO, and PAHO. These collaborations have expanded access to vaccines in low- and middle-income countries, helping overcome cost barriers and logistical challenges.

In addition, school-based vaccination programs have been particularly effective in reaching adolescent populations, which are the primary target for HPV prevention. The Pan American Health Organization's revolving fund and WHO's prequalification process for new vaccines like Cervavac and Walrinvax have also broadened the landscape of accessible options. As countries increasingly aim to meet the WHO's goal of eliminating cervical cancer, HPV vaccination is becoming a central pillar in their national strategies, boosting both public and private sector demand and creating significant market opportunities.

Increased global awareness regarding HPV transmission, associated health risks, and the benefits of vaccination is a major factor driving market growth. Public health campaigns, social media outreach, and school-based education initiatives have played a pivotal role in changing perceptions and encouraging vaccine acceptance. In countries with robust healthcare communication strategies, such as Australia and the UK, HPV vaccine uptake is notably high, reflecting the impact of consistent, evidence-based awareness efforts. Gender-neutral vaccination messaging has also improved acceptance among male populations, particularly in response to the growing incidence of oropharyngeal and anal cancers in men. As stigma around sexual health diminishes and more people recognize the long-term cancer prevention benefits of vaccination, broader demographic groups are being reached. These awareness initiatives are not only increasing demand but are also leading to earlier vaccination, higher compliance rates, and more consistent market growth.

The increasing global prevalence of HPV-related cancers, particularly cervical cancer, is one of the strongest growth drivers of the HPV vaccines market. According to the World Health Organization (WHO), in 2022, cervical cancer was responsible for over 342,000 deaths worldwide, making it the fourth most common cancer among women. Approximately 95% of cervical cancer cases are linked to persistent infection with high-risk HPV types, primarily types 16 and 18. Similarly, the incidence of other HPV-associated cancers-such as oropharyngeal, anal, penile, vaginal, and vulvar cancers-is on the rise, especially in high-income countries. For example, HPV is now responsible for over 70% of oropharyngeal cancers in the United States, a trend that has been steadily increasing over the past decade. This growing disease burden has elevated the role of HPV vaccination in public health agendas. With improved diagnostics and surveillance, and as HPV-related cancer data becomes more robust, the urgency to implement broad vaccination strategies, particularly for adolescents, is accelerating global market demand.

Human Papillomavirus Vaccines Market Report Highlights:

• In 2024, the quadrivalent segment held the largest market share of 75.67%, attributed to its comprehensive protection against four major HPV types-6, 11, 16, and 18. These strains are known to cause nearly 70% of cervical cancer cases and about 90% of genital warts, making the quadrivalent vaccine a key component in HPV immunization strategies worldwide.
• In 2024, the cervical cancer segment dominated the market, capturing a revenue share of 63.78%, driven by increased awareness and strong preventive measures. Cervical cancer is among the most prevalent HPV-related malignancies, primarily caused by HPV types 16 and 18, which are responsible for approximately 70% of all cases.
• In 2024, the hospitals and retail pharmacies segment held the largest revenue share of 54.75% and is projected to experience the fastest growth during the forecast period. This trend is primarily driven by the growing accessibility, convenience, and reliability that these healthcare facilities offer to patients seeking HPV vaccination.
• In 2024, North America led the global market with a share of 39.83%, fueled by extensive immunization coverage, robust public health campaigns, and early adoption of HPV vaccines across both public and private healthcare systems, ensuring broad population protection.
• The global HPV vaccines market is led by several major companies, including Merck & Co., Inc., GlaxoSmithKline plc (GSK), Serum Institute of India Pvt. Ltd., among others. All key companies are strengthening their worldwide presence through strategies like launching new products, forging strategic partnerships, and expanding into new geographic regions.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Disease
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Disease outlook
  • 2.2.3. Distribution channel outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Human Papillomavirus (HPV) Vaccines Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Trends and Outlook
• 3.4. Market Dynamics
  • 3.4.1. Rising prevalence of HPV-related cancers
  • 3.4.2. Government and NGO immunization programs
  • 3.4.3. Growing Awareness and education initiatives
  • 3.4.4. Increase in healthcare expenditure
  • 3.4.5. Advancements in vaccine technology
• 3.5. Market Restraint Analysis
  • 3.5.1. High vaccine costs
  • 3.5.2. Limited Awareness in Underserved Regions
  • 3.5.3. Porter's Five Forces Analysis
  • 3.5.4. PESTEL Analysis

Chapter 4. Human Papillomavirus (HPV) Vaccines Market: Type Estimates & Trend Analysis

• 4.1. Human Papillomavirus (HPV) Vaccines Market: Type Movement Analysis
• 4.2. Human Papillomavirus (HPV) Vaccines Market Estimates and Forecast, by Type
• 4.3. Bivalent
  • 4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.4. Quadrivalent
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Nonavalent
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Human Papillomavirus (HPV) Vaccines Market: Disease Estimates & Trend Analysis

• 5.1. Human Papillomavirus (HPV) Vaccines Market: Disease Movement Analysis
• 5.2. Human Papillomavirus (HPV) Vaccines Market Estimates and Forecast, by Disease
• 5.3. Cervical Cancer
  • 5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.4. Vaginal and Vulvar Cancers
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Anal Cancer
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Oropharyngeal (Head and Neck) Cancers
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Genital Warts
  • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Human Papillomavirus (HPV) Vaccines Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Human Papillomavirus (HPV) Vaccines Market: Distribution Movement Analysis
• 6.2. Human Papillomavirus (HPV) Vaccines Market Estimates and Forecast, by Distribution Channel
• 6.3. Hospitals and Retail Pharmacies
  • 6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Government Suppliers
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Others
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Human Papillomavirus (HPV) Vaccines Market: Regional Estimates & Trend Analysis

• 7.1. Human Papillomavirus (HPV) Vaccines Market Share By Region, 2024 & 2030
• 7.2. Regional Market Share Analysis, 2024 & 2030
• 7.3. Regional Market Dashboard
• 7.4. Global Regional Market Snapshot
• 7.5. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.6. North America
  • 7.6.1. North America Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.6.2. U.S.
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. U.S. Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.6.3. Canada
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Canada Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.6.4. Mexico
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Mexico Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• 7.7. Europe
  • 7.7.1. Europe Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7.2. UK
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. UK Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7.3. Germany
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Germany Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7.4. France
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. France Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7.5. Italy
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Italy Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7.6. Spain
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Competitive Scenario
    • 7.7.6.3. Regulatory Framework
    • 7.7.6.4. Spain Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7.7. Denmark
    • 7.7.7.1. Key Country Dynamics
    • 7.7.7.2. Competitive Scenario
    • 7.7.7.3. Regulatory Framework
    • 7.7.7.4. Denmark Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7.8. Sweden
    • 7.7.8.1. Key Country Dynamics
    • 7.7.8.2. Competitive Scenario
    • 7.7.8.3. Regulatory Framework
    • 7.7.8.4. Sweden Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7.9. Norway
    • 7.7.9.1. Key Country Dynamics
    • 7.7.9.2. Competitive Scenario
    • 7.7.9.3. Regulatory Framework
    • 7.7.9.4. Norway Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• 7.8. Asia Pacific
  • 7.8.1. Asia Pacific Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.8.2. Japan
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Japan Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.8.3. China
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. China Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.8.4. India
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. India Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.8.5. Australia
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Australia Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.8.6. Thailand
    • 7.8.6.1. Key Country Dynamics
    • 7.8.6.2. Competitive Scenario
    • 7.8.6.3. Regulatory Framework
    • 7.8.6.4. Thailand Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.8.7. South Korea
    • 7.8.7.1. Key Country Dynamics
    • 7.8.7.2. Competitive Scenario
    • 7.8.7.3. Regulatory Framework
    • 7.8.7.4. South Korea Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• 7.9. Latin America
  • 7.9.1. Latin America Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.9.2. Brazil
    • 7.9.2.1. Key Country Dynamics
    • 7.9.2.2. Competitive Scenario
    • 7.9.2.3. Regulatory Framework
    • 7.9.2.4. Brazil Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.9.3. Argentina
    • 7.9.3.1. Key Country Dynamics
    • 7.9.3.2. Competitive Scenario
    • 7.9.3.3. Regulatory Framework
    • 7.9.3.4. Argentina Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
• 7.10. MEA
  • 7.10.1. MEA Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.10.2. South Africa
    • 7.10.2.1. Key Country Dynamics
    • 7.10.2.2. Competitive Scenario
    • 7.10.2.3. Regulatory Framework
    • 7.10.2.4. South Africa Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.10.3. Saudi Arabia
    • 7.10.3.1. Key Country Dynamics
    • 7.10.3.2. Competitive Scenario
    • 7.10.3.3. Regulatory Framework
    • 7.10.3.4. Saudi Arabia Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.10.4. UAE
    • 7.10.4.1. Key Country Dynamics
    • 7.10.4.2. Competitive Scenario
    • 7.10.4.3. Regulatory Framework
    • 7.10.4.4. UAE Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)
  • 7.10.5. Kuwait
    • 7.10.5.1. Key Country Dynamics
    • 7.10.5.2. Competitive Scenario
    • 7.10.5.3. Regulatory Framework
    • 7.10.5.4. Kuwait Human Papillomavirus (HPV) Vaccines Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company Categorization
• 8.3. Strategy Mapping
• 8.4. Company Market Share Analysis, 2024
• 8.5. Company Profiles
  • 8.5.1. Merck & Co., Inc.
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. GlaxoSmithKline plc (GSK)
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Serum Institute of India Pvt. Ltd.
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Sanofi Pasteur SA
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Pfizer Inc.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Inovio Pharmaceuticals Inc.
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Walvax Biotechnology Co., Ltd.
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Bharat Biotech International Ltd.
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Johnson & Johnson Services, Inc.
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Moderna, Inc.
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives
  • 8.5.11. Gilead Sciences, Inc.
    • 8.5.11.1. Overview
    • 8.5.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.11.3. Product Benchmarking
    • 8.5.11.4. Strategic Initiatives